flutamide has been researched along with Insulin Sensitivity in 19 studies
Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The few controlled trials performed so far indicate that the addition of metformin and/or flutamide to a hypocaloric diet in obese women with polycystic ovary syndrome (PCOS) effectively influences different phenotypic aspects of the syndrome." | 9.12 | Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. ( Cacciari, M; Cavazza, C; Gambineri, A; Morselli-Labate, AM; Pagotto, U; Pasquali, R; Patton, L; Vaccina, A, 2006) |
| " Metformin is commonly used to treat insulin resistance-glucose intolerance, and flutamide, an androgen receptor (AR) antagonist, is used to target hyperandrogenemia and dyslipidemia." | 7.91 | Effect of metformin and flutamide on insulin, lipogenic and androgen-estrogen signaling, and cardiometabolic risk in a PCOS-prone metabolic syndrome rodent model. ( Diane, A; Ghosh, M; Kupreeva, M; Lehner, R; Proctor, S; Vine, D; Watts, R, 2019) |
| "The authors evaluate the effects of 2 months of treatment with 250 mg flutamide daily on adrenal steroidogenesis (ACTH test) and metabolic parameters (lipids, insulin resistance) in 12 PCOS women aged 33." | 7.72 | Flutamide suppresses adrenal steroidogenesis but has no effect on insulin resistance and secretion and lipid levels in overweight women with polycystic ovary syndrome. ( Dvoráková, K; Hill, M; Stanická, S; Stárka, L; Vondra, K; Vrbíková, J, 2004) |
| "Flutamide-metformin treatment (n = 30) was followed within 3 months by marked decreases in hirsutism score and serum androgens, by a more than 50% increase in insulin sensitivity and by a less atherogenic lipid profile (all P < 0." | 6.71 | Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in nonobese adolescents with ovarian hyperandrogenism. ( Amin, R; de Zegher, F; Dunger, D; Ferrer, A; Ibáñez, L; Ong, K, 2003) |
| "In conclusion, metformin treatment improved insulin sensitivity and decreased androgen levels, and flutamide decreased androgen levels but failed to improve insulin sensitivity in the non-obese women with PCOS." | 6.71 | Metformin versus flutamide in the treatment of metabolic consequences of non-obese young women with polycystic ovary syndrome: a randomized prospective study. ( Aral, Y; Culha, C; Demirbas, B; Karakurt, F; Kosar, F; Sahin, I; Serter, R; Taskapan, C, 2004) |
| "The few controlled trials performed so far indicate that the addition of metformin and/or flutamide to a hypocaloric diet in obese women with polycystic ovary syndrome (PCOS) effectively influences different phenotypic aspects of the syndrome." | 5.12 | Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. ( Cacciari, M; Cavazza, C; Gambineri, A; Morselli-Labate, AM; Pagotto, U; Pasquali, R; Patton, L; Vaccina, A, 2006) |
| " To distinguish the mechanisms of this association, we determined the interactions of PCO with obesity and the influence of ameliorating direct androgenic actions via short-term treatment with the antiandrogen flutamide." | 5.08 | Insulin sensitivity and antiandrogenic therapy in women with polycystic ovary syndrome. ( Diamanti-Kandarakis, E; Georgiadou, E; Hennes, MM; Hoffmann, RG; Kaklas, N; Kissebah, AH; Mitrakou, A; Platanissiotis, D; Raptis, S; Spina, J, 1995) |
| " Metformin is commonly used to treat insulin resistance-glucose intolerance, and flutamide, an androgen receptor (AR) antagonist, is used to target hyperandrogenemia and dyslipidemia." | 3.91 | Effect of metformin and flutamide on insulin, lipogenic and androgen-estrogen signaling, and cardiometabolic risk in a PCOS-prone metabolic syndrome rodent model. ( Diane, A; Ghosh, M; Kupreeva, M; Lehner, R; Proctor, S; Vine, D; Watts, R, 2019) |
| " This study tested whether 1) in utero cotreatment of prenatally T-treated sheep with androgen antagonist (flutamide) or insulin sensitizer (rosiglitazone) prevents juvenile insulin resistance and adult changes in adipocyte size; and 2) visceral adiposity and insulin sensitivity are both unaltered during early adulthood, confirming the predicted developmental trajectory in this animal model." | 3.83 | Developmental Programming: Impact of Gestational Steroid and Metabolic Milieus on Adiposity and Insulin Sensitivity in Prenatal Testosterone-Treated Female Sheep. ( Beckett, E; Cardoso, RC; Chazenbalk, G; Dumesic, D; Keller, E; Madrigal, V; Moeller, J; Padmanabhan, V; Pease, A; Veiga-Lopez, A, 2016) |
| "The authors evaluate the effects of 2 months of treatment with 250 mg flutamide daily on adrenal steroidogenesis (ACTH test) and metabolic parameters (lipids, insulin resistance) in 12 PCOS women aged 33." | 3.72 | Flutamide suppresses adrenal steroidogenesis but has no effect on insulin resistance and secretion and lipid levels in overweight women with polycystic ovary syndrome. ( Dvoráková, K; Hill, M; Stanická, S; Stárka, L; Vondra, K; Vrbíková, J, 2004) |
| "Flutamide-metformin treatment (n = 30) was followed within 3 months by marked decreases in hirsutism score and serum androgens, by a more than 50% increase in insulin sensitivity and by a less atherogenic lipid profile (all P < 0." | 2.71 | Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in nonobese adolescents with ovarian hyperandrogenism. ( Amin, R; de Zegher, F; Dunger, D; Ferrer, A; Ibáñez, L; Ong, K, 2003) |
| "In conclusion, metformin treatment improved insulin sensitivity and decreased androgen levels, and flutamide decreased androgen levels but failed to improve insulin sensitivity in the non-obese women with PCOS." | 2.71 | Metformin versus flutamide in the treatment of metabolic consequences of non-obese young women with polycystic ovary syndrome: a randomized prospective study. ( Aral, Y; Culha, C; Demirbas, B; Karakurt, F; Kosar, F; Sahin, I; Serter, R; Taskapan, C, 2004) |
| "We hypothesized that dyslipidemia and anovulation in nonobese women with polycystic ovary syndrome are essentially secondary to the concerted effects of hyperandrogenism and insulin resistance." | 2.70 | Additive effects of insulin-sensitizing and anti-androgen treatment in young, nonobese women with hyperinsulinism, hyperandrogenism, dyslipidemia, and anovulation. ( De Zegher, F; Dunger, DB; Ferrer, A; Ibáñez, L; Ong, K; Valls, C, 2002) |
| "While the treatment of hyperandrogenism makes use of different drugs already studied, the debate about the use of insulin sensitizing drugs is still open." | 2.42 | Which treatment options should be used in adolescents with polycystic ovary syndrome? ( Barini, A; Di Sebastiano, F; Fulghesu, AM; Lanzone, A; Rossodivita, A; Sagnella, F; Villa, P, 2004) |
| "Hirsutism is the manifestation of hyperandrogenemia in PCOS." | 1.32 | The treatment of polycystic ovary syndrome. ( Ajossa, S; Guerriero, S; Melis, GB; Orrù, M; Paoletti, AM, 2004) |
| "Insulin resistance was observed in both ovarian and nonovarian hyperandrogenism, as distinguished by acute GnRH agonist testing." | 1.29 | The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women. ( Brun, E; Caputo, M; Castello, R; Furlani, L; Magnani, CM; Moghetti, P; Muggeo, M; Negri, C; Tosi, F, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (15.79) | 18.2507 |
| 2000's | 9 (47.37) | 29.6817 |
| 2010's | 5 (26.32) | 24.3611 |
| 2020's | 2 (10.53) | 2.80 |
| Authors | Studies |
|---|---|
| Rolon, S | 1 |
| Huynh, C | 1 |
| Guenther, M | 1 |
| Gardezi, M | 1 |
| Phillips, J | 1 |
| Gehrand, AL | 1 |
| Raff, H | 1 |
| Yawson, EO | 1 |
| Akinola, OB | 1 |
| Kupreeva, M | 1 |
| Diane, A | 1 |
| Lehner, R | 1 |
| Watts, R | 1 |
| Ghosh, M | 1 |
| Proctor, S | 1 |
| Vine, D | 1 |
| Usman, TO | 1 |
| Areola, ED | 1 |
| Badmus, OO | 1 |
| Kim, I | 1 |
| Olatunji, LA | 1 |
| Hurliman, A | 1 |
| Keller Brown, J | 1 |
| Maille, N | 1 |
| Mandala, M | 1 |
| Casson, P | 1 |
| Osol, G | 1 |
| Cardoso, RC | 1 |
| Veiga-Lopez, A | 1 |
| Moeller, J | 1 |
| Beckett, E | 1 |
| Pease, A | 1 |
| Keller, E | 1 |
| Madrigal, V | 1 |
| Chazenbalk, G | 1 |
| Dumesic, D | 1 |
| Padmanabhan, V | 1 |
| Brill, DS | 1 |
| Moenter, SM | 1 |
| Lázaro, I | 1 |
| Díaz, M | 1 |
| Cabré, A | 1 |
| Masana, L | 1 |
| Ibáñez, L | 3 |
| Ong, K | 2 |
| Ferrer, A | 2 |
| Amin, R | 1 |
| Dunger, D | 1 |
| de Zegher, F | 2 |
| Ajossa, S | 1 |
| Guerriero, S | 1 |
| Paoletti, AM | 1 |
| Orrù, M | 1 |
| Melis, GB | 1 |
| Vrbíková, J | 1 |
| Hill, M | 1 |
| Dvoráková, K | 1 |
| Stanická, S | 1 |
| Vondra, K | 1 |
| Stárka, L | 1 |
| Villa, P | 1 |
| Di Sebastiano, F | 1 |
| Rossodivita, A | 1 |
| Sagnella, F | 1 |
| Barini, A | 1 |
| Fulghesu, AM | 1 |
| Lanzone, A | 1 |
| Sahin, I | 1 |
| Serter, R | 1 |
| Karakurt, F | 1 |
| Demirbas, B | 1 |
| Culha, C | 1 |
| Taskapan, C | 1 |
| Kosar, F | 1 |
| Aral, Y | 1 |
| Gambineri, A | 1 |
| Patton, L | 1 |
| Vaccina, A | 1 |
| Cacciari, M | 1 |
| Morselli-Labate, AM | 1 |
| Cavazza, C | 1 |
| Pagotto, U | 1 |
| Pasquali, R | 1 |
| Corbould, A | 1 |
| Diamanti-Kandarakis, E | 1 |
| Mitrakou, A | 1 |
| Hennes, MM | 1 |
| Platanissiotis, D | 1 |
| Kaklas, N | 1 |
| Spina, J | 1 |
| Georgiadou, E | 1 |
| Hoffmann, RG | 1 |
| Kissebah, AH | 1 |
| Raptis, S | 1 |
| Moghetti, P | 1 |
| Tosi, F | 1 |
| Castello, R | 1 |
| Magnani, CM | 1 |
| Negri, C | 1 |
| Brun, E | 1 |
| Furlani, L | 1 |
| Caputo, M | 1 |
| Muggeo, M | 1 |
| Zemtsov, A | 1 |
| Wilson, L | 1 |
| Valls, C | 1 |
| Dunger, DB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Trial of Bicalutamide Versus Placebo in Reproductive-Aged Women With Nonalcoholic Fatty Liver Disease (NAFLD) and Polycystic Ovary Syndrome (PCOS)[NCT05979389] | Phase 1 | 50 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | ||
| Metabolic Syndrome in PCOS: Precursors and Interventions[NCT00442689] | 97 participants (Actual) | Interventional | 2006-07-31 | Completed | |||
| Effects of Inositol Alone or Associated With Alpha-lipoic Acid in Polycystic Ovary Syndrome Treatment[NCT04881851] | 90 participants (Anticipated) | Interventional | 2015-05-07 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in disposition index (DI, insulin secretion corrected for insulin secretion) as measured by frequently-sampled IV glucose tolerance test (DI at study endpoint - baseline DI) (NCT00442689)
Timeframe: 6 months
| Intervention | min^-1 (Mean) |
|---|---|
| Oral Contraceptive - 1 | 1653 |
| Flutamide - 2 | 194 |
| Placebo - 3 | -184 |
Change in fat percentage as measured by DEXA scan over the study period (Fat percentage at study endpoint - baseline fat percentage) (NCT00442689)
Timeframe: 6 months
| Intervention | percentage of body mass (Mean) |
|---|---|
| Oral Contraceptive - 1 | 0.4 |
| Flutamide - 2 | -1.9 |
| Placebo - 3 | -1.9 |
Change in high-density lipoprotein (HDL) levels during study period (HDL level at study endpoint - baseline HDL) (NCT00442689)
Timeframe: 6 months
| Intervention | mg/dL (Mean) |
|---|---|
| Oral Contraceptive - 1 | 6 |
| Flutamide - 2 | -5 |
| Placebo - 3 | -2 |
Change in low-density lipoprotein (LDL) levels over the study period (LDL level at study endpoint - baseline LDL level) (NCT00442689)
Timeframe: 6 months
| Intervention | mg/dL (Mean) |
|---|---|
| Oral Contraceptive - 1 | -6 |
| Flutamide - 2 | -9 |
| Placebo - 3 | -7 |
Change in maximal aerobic exercise capacity (VO2 max) over the study period (VO2 max at study endpoint - baseline VO2 max) (NCT00442689)
Timeframe: 6 months
| Intervention | L/min (Mean) |
|---|---|
| Oral Contraceptive - 1 | -0.5 |
| Flutamide - 2 | -1.6 |
| Placebo - 3 | 1.1 |
Change in resting energy expenditure (REE) over the study period (REE at study endpoint - baseline REE) (NCT00442689)
Timeframe: 6 months
| Intervention | Kcal/day (Mean) |
|---|---|
| Oral Contraceptive - 1 | 7 |
| Flutamide - 2 | -79 |
| Placebo - 3 | -88 |
Change in visceral adipose tissue (VAT) volume as measured by MRI (VAT at study endpoint - baseline VAT) (NCT00442689)
Timeframe: 6 months
| Intervention | L (Mean) |
|---|---|
| Oral Contraceptive - 1 | -0.1 |
| Flutamide - 2 | -0.1 |
| Placebo - 3 | 0.1 |
1 review available for flutamide and Insulin Sensitivity
| Article | Year |
|---|---|
Which treatment options should be used in adolescents with polycystic ovary syndrome?
Topics: Adolescent; Adolescent Health Services; Adult; Androgen Antagonists; Estrogens; Female; Flutamide; H | 2004 |
6 trials available for flutamide and Insulin Sensitivity
| Article | Year |
|---|---|
Fatty acid-binding protein-4 plasma levels are associated to metabolic abnormalities and response to therapy in girls and young women with androgen excess.
Topics: Adolescent; Androgen Antagonists; Biomarkers; Body Mass Index; Child; Contraceptives, Oral, Combined | 2011 |
Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in nonobese adolescents with ovarian hyperandrogenism.
Topics: Adipose Tissue; Androgen Antagonists; Child; Dose-Response Relationship, Drug; Drug Therapy, Combina | 2003 |
Metformin versus flutamide in the treatment of metabolic consequences of non-obese young women with polycystic ovary syndrome: a randomized prospective study.
Topics: Adolescent; Adult; Blood Glucose; Body Mass Index; Dehydroepiandrosterone Sulfate; Female; Flutamide | 2004 |
Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study.
Topics: Adipose Tissue; Adult; Diet, Reducing; Drug Therapy, Combination; Energy Intake; Female; Flutamide; | 2006 |
Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study.
Topics: Adipose Tissue; Adult; Diet, Reducing; Drug Therapy, Combination; Energy Intake; Female; Flutamide; | 2006 |
Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study.
Topics: Adipose Tissue; Adult; Diet, Reducing; Drug Therapy, Combination; Energy Intake; Female; Flutamide; | 2006 |
Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study.
Topics: Adipose Tissue; Adult; Diet, Reducing; Drug Therapy, Combination; Energy Intake; Female; Flutamide; | 2006 |
Insulin sensitivity and antiandrogenic therapy in women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Androgen Antagonists; Androgens; Female; Flutamide; Humans; Insulin Resistance; O | 1995 |
Additive effects of insulin-sensitizing and anti-androgen treatment in young, nonobese women with hyperinsulinism, hyperandrogenism, dyslipidemia, and anovulation.
Topics: Adult; Androgen Antagonists; Anovulation; Drug Combinations; Female; Flutamide; Humans; Hyperandroge | 2002 |
12 other studies available for flutamide and Insulin Sensitivity
| Article | Year |
|---|---|
Insulin and glucose responses to hypoxia in male and female neonatal rats: Effects of the androgen receptor antagonist flutamide.
Topics: Androgen Receptor Antagonists; Animals; Animals, Newborn; Disease Models, Animal; Female; Flutamide; | 2021 |
Hippocampal cellular changes in androgen deprived insulin resistant rats.
Topics: Androgen Antagonists; Animals; Astrocytes; Blood Glucose; Flutamide; Hippocampus; Insulin; Insulin R | 2021 |
Effect of metformin and flutamide on insulin, lipogenic and androgen-estrogen signaling, and cardiometabolic risk in a PCOS-prone metabolic syndrome rodent model.
Topics: Androgen Antagonists; Animals; Apolipoprotein B-100; Apolipoprotein B-48; Apolipoproteins B; Blood G | 2019 |
Sodium acetate and androgen receptor blockade improve gestational androgen excess-induced deteriorated glucose homeostasis and antioxidant defenses in rats: roles of adenosine deaminase and xanthine oxidase activities.
Topics: Adenosine Deaminase; Androgen Receptor Antagonists; Animals; Animals, Newborn; Antioxidants; Female; | 2018 |
Hyperandrogenism and Insulin Resistance, Not Changes in Body Weight, Mediate the Development of Endothelial Dysfunction in a Female Rat Model of Polycystic Ovary Syndrome (PCOS).
Topics: Androgen Antagonists; Androgens; Animals; Arteries; Blood Pressure; Body Weight; Dihydrotestosterone | 2015 |
Developmental Programming: Impact of Gestational Steroid and Metabolic Milieus on Adiposity and Insulin Sensitivity in Prenatal Testosterone-Treated Female Sheep.
Topics: Adiposity; Animals; Disease Models, Animal; Embryonic Development; Female; Flutamide; Insulin Resist | 2016 |
Androgen receptor antagonism and an insulin sensitizer block the advancement of vaginal opening by high-fat diet in mice.
Topics: Analysis of Variance; Androgen Antagonists; Animals; Body Weight; Diet, Fat-Restricted; Dietary Fats | 2009 |
The treatment of polycystic ovary syndrome.
Topics: Adult; Androgen Antagonists; Cabergoline; Cardiovascular Diseases; Clomiphene; Cyproterone Acetate; | 2004 |
Flutamide suppresses adrenal steroidogenesis but has no effect on insulin resistance and secretion and lipid levels in overweight women with polycystic ovary syndrome.
Topics: 17-Hydroxysteroid Dehydrogenases; Adrenal Glands; Adrenocorticotropic Hormone; Adult; Androgen Antag | 2004 |
Chronic testosterone treatment induces selective insulin resistance in subcutaneous adipocytes of women.
Topics: Adipocytes; Adult; Analysis of Variance; Biological Transport; Cell Differentiation; Cells, Cultured | 2007 |
The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women.
Topics: Adult; Androgen Antagonists; Androgens; Buserelin; Female; Flutamide; Glucose Clamp Technique; Human | 1996 |
Successful treatment of hirsutism in HAIR-AN syndrome using flutamide, spironolactone, and birth control therapy.
Topics: Acanthosis Nigricans; Adolescent; Androgen Antagonists; Contraceptives, Oral, Combined; Contraceptiv | 1997 |